Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)

Jyoji Nakagawara, Kazuo Minematsu, Yasushi Okada, Norio Tanahashi, Shinji Nagahiro, Etsuro Mori, Yukito Shinohara, Takenori Yamaguchi

Research output: Contribution to journalArticlepeer-review

119 Citations (Scopus)

Abstract

Background and Purpose-: In Japan, alteplase at 0.6 mg/kg was approved in October 2005 for use within 3 hours of stroke onset by the Ministry of Health, Labor and Welfare (MHLW). The aim of the Japan post-Marketing Alteplase Registration Study (J-MARS), which was requested by MHLW at the time of approval, was to assess the safety and efficacy of 0.6 mg/kg alteplase in routine clinical practice for the Japanese. Methods-: A total of 7492 patients from 942 centers were enrolled in the J-MARS, an open-label, nonrandomized, observational study, from October 2005 to October 2007. Primary outcome measures were symptomatic intracranial hemorrhage (a deterioration in NIHSS score ≥4 from baseline) and favorable outcome (modified Rankin Scale score, 0-1) at 3 months after stroke onset. Results-: The proportion of patients with symptomatic intracranial hemorrhage in 7492 patients (safety analysis) was 3.5% (95% confidence interval [CI], 3.1%-3.9%) within 36 hours and 4.4% (95% CI, 3.9%-4.9%) at 3 months. The overall mortality rate was 13.1% (95% CI, 12.4%-13.9%) and the proportion of patients with fatal symptomatic intracranial hemorrhage was 0.9% (95% CI, 0.7%-1.2%). The outcomes at 3 months were available for 4944 patients and the proportion of favorable outcome (efficacy analysis) was 33.1% (95% CI, 31.8%-34.4%). The subgroup analysis in patients between 18 and 80 years with a baseline NIHSS score <25 demonstrated that favorable outcome at 3 months was 39.0% (95% CI, 37.4%-40.6%). Conclusions-: These data suggest that 0.6 mg/kg intravenous alteplase within 3 hours of stroke onset could be safe and effective in routine clinical practice for the Japanese.

Original languageEnglish
Pages (from-to)1984-1989
Number of pages6
JournalStroke
Volume41
Issue number9
DOIs
Publication statusPublished - 2010 Sep

Keywords

  • acute ischemic stroke
  • alteplase
  • postmarketing registration
  • thrombolysis
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)'. Together they form a unique fingerprint.

Cite this